GlassScriptPhysician profile
Kelli Janet Clair
NPI 1902107295
$12,407.16
in general payments reported to CMS, 2019-2025
29 companies · $2,126 in 2025
The $2,126 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,393 · 2022: $2,385 · 2023: $3,358 · 2024: $2,146 · 2025: $2,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,524 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,524.14 |
| Education | $105.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,940.31 | 2021-2025 | |
| Abbvie INC. | $1,624.75 | 2021-2025 | |
| Janssen Biotech, INC. | $1,125.67 | 2021-2025 | Tremfya |
| Genzyme Corporation | $897.08 | 2021-2025 | |
| Ucb, INC. | $827.55 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $724.74 | 2022-2025 | Sotyktu |
| Incyte Corporation | $592.10 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $500.74 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $488.12 | 2021-2024 | Adbry |
| Dermavant Sciences, INC. | $486.71 | 2023-2024 | Vtama |
| Amgen INC. | $462.12 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $440.34 | 2021-2025 | Ilumya, Winlevi |
| Pfizer INC. | $380.72 | 2021-2023 | |
| Galderma Laboratories, L.P. | $349.19 | 2021-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $348.35 | 2021-2025 | Dupixent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $302.27 | 2023-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.19 | 2022-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $133.11 | 2021-2024 | Cabtreo, Arazlo, Jublia |
| Dermira, INC. | $105.88 | 2021 | |
| Organon LLC | $105.44 | 2024-2025 | Vtama |
| Vyne Pharmaceuticals INC. | $93.04 | 2021 | |
| Epi Health, LLC | $78.81 | 2021-2022 | |
| Almirall LLC | $61.72 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $46.54 | 2022-2023 | |
| Kyowa Kirin, INC. | $40.49 | 2021-2023 | Poteligeo |
| Krystal Biotech INC | $25.42 | 2023 | Vyjuvek |
| Medimetriks Pharmaceuticals, INC. | $19.03 | 2022 | |
| Verrica Pharmaceuticals INC. | $15.09 | 2024 | Ycanth |
| Biofrontera INC. | $11.64 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Clair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.